Marschall, Hanns-Ulrich

Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist

Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism

Gut microbiota and healthDrug Transport and Resistance Mechanisms

Cited by 2,331

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology

Liver Disease Diagnosis and TreatmentDrug Transport and Resistance Mechanisms

Cited by 931

Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota

Wang, J., Thingholm, L. B., Skiecevičienė, J., Rausch, P., Kummen, M., Hov, J. R., Degenhardt, F., Heinsen, F.-A., Rühlemann, M. C., Szymczak, S., et al. (2016) · Nature Genetics

Gut microbiota and healthGenetic Associations and Epidemiology

Cited by 625

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 576

Whole-genome sequencing of patients with rare diseases in a national health system

Turro, E., Astle, W. J., Megy, K., Gräf, S., Greene, D., Shamardina, O., Allen, H. L., Sanchis-Juan, A., Frontini, M., Thys, C., et al. (2020) · Nature

Genomics and Rare DiseasesGenetic Associations and Epidemiology

Cited by 554

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

Role of bile acids in metabolic control

Molinaro, A., Wahlström, A., & Marschall, H.-U. (2018) · Trends in Endocrinology & Metabolism

Drug Transport and Resistance MechanismsGut microbiota and health

Cited by 447

The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls

Kummen, M., Holm, K., Anmarkrud, J. A., Nygård, S., Vesterhus, M., Høivik, M. L., Trøseid, M., Marschall, H.-U., Schrumpf, E., Moum, B., et al. (2017) · Gut

Gut microbiota and healthLiver Diseases and Immunity

Cited by 426

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 394

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 391

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice†

Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 355

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 297

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 281

Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment

Schneider, K. M., Mohs, A., Gui, W., Galvez, E. J. C., Candels, L. S., Hoenicke, L., Muthukumarasamy, U., Holland, C. H., Elfers, C., Kilic, K., et al. (2022) · Nature Communications

Gut microbiota and healthImmune cells in cancer

Cited by 225

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis

Ponsioen, C. Y., Arnelo, U., Bergquist, A., Rauws, E. A., Paulsen, V., Cantú, P., Parzanese, I., De Vries, E. M., van Munster, K. N., Said, K., et al. (2018) · Gastroenterology

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 112

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy

Geenes, V., Chambers, J., Khurana, R., Shemer, E. W., Sia, W., Mandair, D., Elias, E., Marschall, H.-U., Hague, W., & Williamson, C. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology

Pregnancy and Medication ImpactPregnancy and preeclampsia studies

Cited by 98

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2−/− mice by modulating composition, signalling and excretion of faecal bile acids

Fuchs, C. D., Paumgartner, G., Mlitz, V., Kunczer, V., Halilbasic, E., Leditznig, N., Wahlström, A., Ståhlman, M., Thüringer, A., Kashofer, K., et al. (2018) · Gut

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 76

Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis

Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 52

De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures

Ito, Y., Carss, K. J., Duarte, S. T., Hartley, T., Keren, B., Kurian, M. A., Marey, I., Charles, P., Mendonça, C., Nava, C., et al. (2018) · The American Journal of Human Genetics

Genetics and Neurodevelopmental DisordersGenomics and Rare Diseases

Cited by 41